International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 58

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in *Cumulative List No. 12, 2007* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 58

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la *Liste récapitulative No. 12, 2007* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 58

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en *Cumulative List No. 12, 2007* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

alogliptinum

alogliptin	2-({6-[(3*R*)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}methyl)benzonitrile
alogliptine	2-({6-[(3*R*)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}méthyl)benzonitrile
alogliptina	2-({6-[(3*R*)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il}metil)benzonitrilo

$C_{18}H_{21}N_5O_2$



alvespimycinum

alvespimycin	(4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-19-{[2-(dimethylamino)ethyl]amino}-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
alvespimycine	carbamate de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-19-{[2-(diméthylamino)éthyl]amino}-13-hydroxy-8,14-diméthoxy-4,10,12,16-tetraméthyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaén-9-yle
alvespimicina	carbamato de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-19-[[2-(dimetilamino)etil]amino]-13-hidroxi-4,10,12,16-tetrametil-8,14-dimetoxi-3,20,22-trioxo-2-azabiciclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ilo

$C_{32}H_{48}N_4O_8$



amifampridinum

amifampridine	pyridine-3,4-diamine
amifampridine	pyridine-3,4-diamine
amifampridina	piridina-3,4-diamina

$C_5H_7N_3$



balamapimodum

balamapimod	4-({3-chloro-4-[(1-methyl-1*H*-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]quinoline-3-carbonitrile
balamapimod	4-({3-chloro-4-[(1-méthyl-1*H*-imidazol-2-yl)sulfanyl]phényl}amino]-6-méthoxy-7-[4-(pyrrolidin-1-yl)pipéridin-1-yl]quinoléine-3-carbonitrile
balamapimod	4-({3-cloro-4-[(1-metil-1*H*-imidazol-2-il)sulfanil]fenil}amino]-6-metoxi-7-[4-(pirrolidin-1-il)piperidin-1-il]quinolina-3-carbonitrilo

$C_{30}H_{32}ClN_7OS$



bevirimatum

bevirimat	3β-(3-carboxy-3-methylbutanoyloxy)lup-20(29)-en-28-oic acid
bévirimat	acide 3β-(3-carboxy-3-méthylbutanoyloxy)lup-20(29)-én-28-oïque
bevirimat	ácido 3β-(3-carboxi-3-metilbutanoiloxi)lup-20(29)-en-28-oico

$C_{36}H_{56}O_6$



carisbamatum

carisbamate (2*S*)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate

carisbamate carbamate de (2*S*)-2-(2-chlorophényl)-2-hydroxyéthyle

carisbamato carbamato de (2*S*)-2-(2-clorofenil)-2-hidroxietilo

$C_9H_{10}ClNO_3$



cevipabulinum

cevipabulin 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-*N*-[(1*S*)-1,1,1-trifluoropropan-2-yl][1,2,4]triazolo[1,5-*a*]pyrimidin-7-amine

cévipabuline 5-chloro-6-{2,6-difluoro-4-[3-(méthylamino)propoxy]phényl}-*N*-[(1*S*)-1,1,1-trifluoropropan-2-yl][1,2,4]triazolo[1,5-*a*]pyrimidin-7-amine

cevipabulina 5-cloro-6-à2,6-difluoro-4-[3-(metilamino)propoxi]fenil}-*N*-[(1*S*)-1,1,1-trifluoropropan-2-il][1,2,4]triazolo[1,5-*a*]pirimidin-7-amina

$C_{18}H_{18}ClF_5N_6O$



dalcetrapibum

dalcetrapib *S*-{2-[1-(2-ethylbutyl)cyclohexanecarboxamido]= phenyl} 2-methylpropanethioate

dalcétrapib 2-méthylpropanethioate de *S*-[2-[[[1-(2-éthylbutyl)= cyclohexanecarboxamido]phényle]

dalcetrapib 2-metilpropanotioato de *S*-[2-[[[1-(2-etilbutil)= ciclohexanocarboxamido]fenilo]

$C_{23}H_{35}NO_2S$



firategrastum

firategrast	(2*S*)-2-(2,6-difluorobenzamido)-3-[4'-(ethoxymethyl)-2',6'-dimethoxy-[1,1'-biphenyl]-4-yl]propanoic acid
firatégrast	acide (2*S*)-2-(2,6-difluorobenzamido)-3-[4'-(éthoxyméthyl)-2',6'-diméthoxy-[1,1'-biphényl]-4-yl]propanoïque
firategrast	ácido (2*S*)-2-(2,6-difluorobenzamido)-3-[4'-(etoximetil)-2',6'-dimetoxi-[1,1'-bifenil]-4-il]propanoico

$C_{27}H_{27}F_2NO_6$



giripladibum

giripladib	4-{3-[5-chloro-1-(diphenylmethyl)-2-(2-{[2-(trifluoromethyl)=phenyl]methanesulfonamido}ethyl)-1*H*-indol-3-yl]propyl}benzoic acid
giripladib	acide 4-{3-[5-chloro-1-(diphénylméthyl)-2-(2-{[2-(trifluoromethyl)=phényl]méthanesulfonamido}éthyl)-1*H*-indol-3-yl]propyl}benzoïque
giripladib	ácido 4-{3-[5-cloro-1-(difenilmetil)-2-(2-{[2-(trifluorometil)fenil]=metanesulfonamido}etil)-1*H*-indol-3-il]propil}benzoico

$C_{41}H_{36}ClF_3N_2O_4S$



imepitoinum

imepitoin — 1-(4-chlorophenyl)-4-(morpholin-4-yl)-1,5-dihydro-2*H*-imidazol-2-one

imépitoïne — 1-(4-chlorophényl)-4-(morpholin-4-yl)-1,5-dihydro-2*H*-imidazol-2-one

imepitoina — 1-(4-clorofenil)-4-(morfolin-4-il)-1,5-dihidro-2*H*-imidazol-2-ona

$C_{13}H_{14}ClN_3O_2$



isavuconazolum

isavuconazole — 4-{2-[(2*R*,3*R*)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1*H*-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile

isavuconazole — 4-{2-[(2*R*,3*R*)-3-(2,5-difluorophényl)-3-hydroxy-4-(1*H*-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile

isavuconazol — 4-{2-[(2*R*,3*R*)-3-(2,5-difluorofenil)-3-hidroxi-4-(1*H*-1,2,4-triazol-1-il)butan-2-il]-1,3-tiazol-4-il}benzonitrilo

$C_{22}H_{17}F_2N_5OS$



isavuconazonii chloridum

isavuconazonium chloride — 1-{(2*R*,3*R*)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl}-4-{(1*RS*)-1-[methyl-(3-{[(methylamino)acetyloxy]methyl}pyridin-2-yl)carbamoyloxy]ethyl}-*1*,2,4-triazolium chloride

chlorure d'isavuconazonium — chlorure de 1-{(2*R*,3*R*)-3-[4-(4-cyanophényl)-1,3-thiazol-2-yl]-2-(2,5-difluorophényl)-2-hydroxybutyl}-4-{(1*RS*)-1-[méthyl-(3-{[(méthylamino)acétyloxy]méthyl}pyridin-2-yl)carbamoyloxy]éthyl}-1,2,4-triazolium

cloruro de isavuconazonio — cloruro de 1-{(2*R*,3*R*)-3-[4-(4-cianofenil)-1,3-tiazol-2-il]-2-(2,5-difluorofenil)-2-hidroxibutil}-4-{(1*RS*)-1-[metil-(3-{[(metilamino)acetiloxi]metil}piridin-2-il)carbamoiloxi]etil}-1,2,4-triazolium

$C_{35}H_{35}ClF_2N_8O_5S$



and epimer at C*
et l'épimère en C*
y el epímero al C*

linaclotidum

linaclotide [9-L-tyrosine]heat-stable enterotoxin (*Escherichia coli*)-(6-19)-peptide

linaclotide [9-L-tyrosine]entérotoxine thermostable (*Escherichia coli*)-(6-19)-peptide

linaclotida [9-L-tirosina]enterotoxina termoestable (*Escherichia coli*)-(6-19)-péptido

$C_{59}H_{79}N_{15}O_{21}S_6$



litenimodum

litenimod *P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-thymidine

liténimod *P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-thymidine

litenimod

P-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidill-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-timidina

$C_{256}H_{322}N_{95}O_{129}P_{25}S_{25}$

(3'-5')d(*P*-thio) (T-A-A-A-C-G-T-T-A-T-A-A-C-
G-T-T-A-T-G-A-C-G-T-C-A-T)

managlinatum dialanetilum

managlinat dialanetil

diethyl *N,N'*-{5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-ylphosphonoyl}di-L-alaninate

managlinat dialanétil

N,N'-{5-[2-amino-5-(2-méthylpropyl)-1,3-thiazol-4-yl]furan-2-ylphosphonoyl}di-L-alaninate de diéthyle

managlinat dialanetilo

N,N'-{5-[2-amino-5-(2-metilpropil)-1,3-tiazol-4-il]furan-2-ilfosfonoil}=di-L-alaninato de dietilo

$C_{21}H_{33}N_4O_6PS$



masitinibum

masitinib

4-[(4-methylpiperazin-1-yl)methyl]-*N*-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide

masitinib

4-[(4-méthylpipérazin-1-yl)méthyl]-*N*-(4-méthyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phényl)benzamide

masitinib

4-[(4-metilpiperazin-1-il)metil]-*N*-(4-metil-3-{[4-(piridin-3-il)-1,3-tiazol-2-il]amino}fenil)benzamida

$C_{28}H_{30}N_6OS$



methylnaltrexonii bromidum

methylnaltrexone bromide

(17*S*)-17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxo-14β-morphinanium bromide

bromure de méthylnaltrexone

bromure de (17*RS*)-17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxy-17-méthyl-6-oxomorphinanium

bromuro de metilnaltrexona

bromuro de (17*RS*)-17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroxi-17-metil-6-oxomorfinanio

$C_{21}H_{26}BrNO_4$



and epimer at N^+
et l'épimère en N^+
y el epímero al N^+

naptumomabum estafenatoxum*

naptumomab estafenatox

immunoglobulin fragment, anti-[trophoblast glycoprotein (TPBG, 5T4)] monoclonal 5T4 gamma1 heavy chain fragment fusion protein [*Mus musculus* VH (5T4V14: H41>P, S44>G, I69>T, V113>G)-IGHG1_CH1)] - [Glycyl-Glycyl-Prolyl] - superantigen SEA/E-120 (synthetic), non-disulfide linked with monoclonal 5T4 kappa light chain [*Mus musculus* V-KAPPA (5T4V18: F10>S, T45>K, I63>S, F73>L, T77>S, L78>V, L83>A)-IGKC]

naptumomab estafénatox

immunoglobuline fragment, anti-[glycoprotéine du trophoblaste (TPBG, 5T4)] protéine de fusion du fragment de la chaîne lourde gamma1 du monoclonal 5T4 [*Mus musculus* VH (5T4V14: H41>P, S44>G, I69>T, V113>G)-IGHG1_CH1)]- [Glycyl-Glycyl-Prolyl] - superantigène SEA/E-120 (synthétique), associée de manière non covalente à la chaîne légère kappa du monoclonal 5T4 [*Mus musculus* V-KAPPA (5T4V18: F10>S, T45>K, I63>S, F73>L, T77>S, L78>V, L83>A)-IGKC]

naptumomab estafenatox

fragmento de inmunoglobulina, anti-[glicoproteína de trofoblasto (TPBG, 5T4)] proteína de fusión del fragmento de la cadena pesada gamma1 del monoclonal 5T4 [*Mus musculus* VH (5T4V14: H41>P, S44>G, I69>T, V113>G)-IGHG1_CH1)] - [Glicil-Glicil-Prolil]– superantígeno SEA/E-120 (sintético), asociada no covalentemente a la cadena ligera kappa del monoclonal 5T4 [*Mus musculus* V-KAPPA (5T4V18: F10>S, T45>K, I63>S, F73>L, T77>S, L78>V, L83>A)-IGKC]

$C_{3255}H_{5025}N_{855}O_{1050}S_{18}$

Heavy chain GGP toxin / Chaîne lourde GGP toxine / Cadena pesada GGP toxina

EVQLQQSGPD	LVKPGASVKI	SCKASGYSFT	GYYMHWVKQS	PGKGLEWIGR	50
INPNNGVTLY	NQKFKDKATL	TVDKSSTTAY	MELRSLTSED	SAVYYCARST	100
MITNYVMDYW	GQGTSVTVSS	AKTTPPSVYP	LAPGSAAQTN	SMVTLGCLVK	150
GYFPEPVTVT	WNSGSLSSGV	HTFPAVLQSD	LYTLSSSVTV	PSSTWPSETV	200
TCNVAHPASS	TKVDKKIVPR	DSGGPSEKSE	EINEKDLRKK	SELQGTALGN	250
LKQIYYYNSK	AITSSEKSAD	QFLTNTLLFK	GFFTGHPWYN	DLLVDLGSTA	300
ATSEYEGSSV	DLYGAYYGYQ	CAGGTPNKTA	CMYGGVTLHD	NNRLTEEKKV	350
PINLWIDGKQ	TTVPIDKVKT	SKKEVTVQEL	DLQARHYLHG	KFGLYNSDSF	400
GGKVQRGLIV	FHSSEGSTVS	YDLFDAQGQY	PDTLLRIYRD	NTTISSTSLS	450
ISLYLYTT				458	

Light chain / Chaîne légère / Cadena ligera

SIVMTQTPTS	LLVSAGDRVT	ITCKASQSVS	NDVAWYQQKP	GQSPKLLISY	50'
TSSRYAGVPD	RFSGSGYGTD	FTLTISSVQA	EDAAVYFCQQ	DYNSPPTFGG	100'
GTKLEIKRAD	AAPTVSIFPP	SSEQLTSGGA	SVVCFLNNFY	PKDINVKWKI	150'
DGSERQNGVL	NSWTDQDSKD	STYSMSSTLT	LTKDEYERHN	SYTCEATHKT	200'
STSPIVKSFN	RNES				214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 23'-88' 134'-194' 147-202 321-331

nemonoxacinum

nemonoxacin — 7-[(3*S*,5*S*)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

némonoxacine — acide 7-[(3*S*,5*S*)-3-amino-5-méthylpipéridin-1-yl]-1-cyclopropyl-8-méthoxy-4-oxo-1,4-dihydroquinoléine-3-carboxylique

nemonoxacino — ácido 7-[(3*S*,5*S*)-3-amino-5-metilpiperidin-1-il]-1-ciclopropil-8-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{20}H_{25}N_3O_4$



obinepitidum

obinepitide — [34-L-glutamine]pancreatic hormone (human)

obinépitide — [34-L-glutamine]hormone pancréatique humaine

obinepitida — [34-L-glutamina]hormona pancreática humana

$C_{185}H_{288}N_{54}O_{55}S_2$

H-Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-
10
Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-
20
Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Gln-Arg-Tyr-NH_2
30

ozenoxacinum

ozenoxacin — 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

ozénoxacine — acide 1-cyclopropyl-8-méthyl-7-[5-méthyl-6-(méthylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

ozenoxacino — ácido 1-ciclopropil-7-[5-metil-6-(metilamino)piridin-3-il]-8-metil-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{21}H_{21}N_3O_3$



padeliporfinum

padeliporfin — dihydrogen (3-{(7*S*,8*S*,17*R*,18*R*)-13-acetyl-18-ethyl-5-(-2-methoxy-2-oxoethyl)-2,8,12,17-tetramethyl-3-[(2-sulfonatoethyl)carbamoyl]-7,8,17,18-tetrahydroporphyrin-7-yl}propanoato)palladium

padéliporfine — dihydrogéno(3-{(7*S*,8*S*,17*R*,18*R*)-13-acétyl-18-éthyl-5-(2-méthoxy-2-oxoéthyl)-2,8,12,17-tétraméthyl-3-[(2-sulfonatoéthyl)carbamoyl]-7,8,17,18-tétrahydroporphirin-7-yl}propanoato)palladium

padeliporfina — dihidrógeno(3-{(7*S*,8*S*,17*R*,18*R*)-13-acetil-18-etil-5-(2-metoxi-2-oxoetil)-2,8,12,17-tetrametil-3-[(2-sulfonatoetil)carbamoil]-7,8,17,18-tetrahidroporfirin-7-il}propanoato)paladio

$C_{37}H_{43}N_5O_9PdS$



pamapimodum

pamapimod — 6-(2,4-difluorophenoxy)-2-[(1,5-dihydroxypentan-3-yl)amino]-8-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one

pamapimod — 6-(2,4-difluorophénoxy)-2-[(1,5-dihydroxypentan-3-yl)amino]-8-méthylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one

pamapimod — 6-(2,4-difluorofenoxi)-2-[(1,5-dihidroxipentan-3-il)amino]-8-metilpirido[2,3-*d*]pirimidin-7(8*H*)-ona

$C_{19}H_{20}F_2N_4O_4$



panobinostatum

panobinostat	(2*E*)-*N*-hydroxy-3-[4-({[2-(2-methyl-1*H*-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
panobinostat	(2*E*)-*N*-hydroxy-3-[4-({[2-(2-méthyl-1*H*-indol-3-yl)éthyl]amino}méthyl)phényl]prop-2-énamide
panobinostat	(2*E*)-*N*-hidroxi-3-[4-({[2-(2-metil-1*H*-indol-3-il)etil]amino}metil)fenil]prop-2-enamida

$C_{21}H_{23}N_3O_2$



pardoprunoxum

pardoprunox	7-(4-methylpiperazin-1-yl)-1,3-benzoxazol-2(3*H*)-one
pardoprunox	7-(4-méthylpipérazin-1-yl)-1,3-benzoxazol-2(3*H*)-one
pardoprunox	7-(4-metilpiperazin-1-il)-1,3-benzoxazol-2(3*H*)-ona

$C_{12}H_{15}N_3O_2$



resatorvidum

resatorvid	ethyl (6*R*)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate
résatorvid	(6*R*)-6-[(2-chloro-4-fluorophényl)sulfamoyl]cyclohex-1-ène-1-carboxylate d'éthyle
resatorvid	(6*R*)-6-[(2-cloro-4-fluorofenil)sulfamoil]ciclohex-1-eno-1-carboxilato de etilo

$C_{15}H_{17}ClFNO_4S$



rusalatidum

rusalatide	human prothrombin-(508-530)-peptidamide (thrombin heavy chain fragment (TRAP 508))
rusalatide	prothrombine humaine-(508-530)-peptidamide (fragment de la chaîne lourde de la thrombine (TRAP 508))
rusalatida	protrombina humana-(508-530)-peptidamida (fragmento de la cadena pesada de la trombina (TRAP 508))

$C_{97}H_{147}N_{29}O_{35}S$

H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-
Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH_2

senicapocum

senicapoc	2,2-bis(4-fluorophenyl)-2-phenylacetamide
sénicapoc	2,2-bis(4-fluorophényl)-2-phénylacétamide
senicapoc	2-fenil-2,2-bis(4-fluorofenil)acetamida

$C_{20}H_{15}F_2NO$



tanespimycinum

tanespimycin	(4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-[(prop-2-en-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
tanespimycine	carbamate de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13-hydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3,20,22-trioxo-19-[(prop-2-én-1-yl)amino]-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaén-9-yle
tanespimicina	carbamato de (4*E*,6*Z*,8*S*,9*S*,10*E*,12*S*,13*R*,14*S*,16*R*)-13-hidroxi-8,14-dimetoxi-4,10,12,16-tetrametil-3,20,22-trioxo-19-[(prop-2-en-1-il)amino]-2-azabiciclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ilo

$C_{31}H_{43}N_3O_8$



telatinibum

telatinib — 4-[({4-[(4-chlorophenyl)amino]furo[2,3-*d*]pyridazin-7-yl}oxy)methyl]-*N*-methylpyridine-2-carboxamide

télatinib — 4-[({4-[(4-chlorophényl)amino]furo[2,3-*d*]pyridazin-7-yl}oxy)méthyl]-*N*-méthylpyridine-2-carboxamide

telatinib — 4-[({4-[(4-clorofenil)amino]furo[2,3-*d*]piridazin-7-il}oxi)metil]-*N*-metilpiridina-2-carboxamida

$C_{20}H_{16}ClN_5O_3$



tesamorelinum

tesamorelin — (3*E*)-hex-3-enoylsomatoliberin (human GHRH)

tésamoréline — (3*E*)-hex-3-enoylsomatolibérine humaine

tesamorelina — (3*E*)-hex-3-enoilsomatoliberina humana

$C_{221}H_{366}N_{72}O_{67}S$



ulipristalum

ulipristal — 11β-[4-(dimethylamino)phenyl]-17-hydroxy-19-norpregna-4,9-diene-3,20-dione

ulipristal — 11β-[4-(diméthylamino)phényl]-17-hydroxy-19-norprégna-4,9-diène-3,20-dione

ulipristal — 11β-[4-(dimetilamino)fenil]-17-hidroxi-19-norpregna-4,9-dieno-3,20-diona

$C_{28}H_{35}NO_3$



vernakalantum

vernakalant	(3*R*)-1-{(1*R*,2*R*)-2-[2-(3,4-dimethoxyphenyl)ethoxy]= cyclohexyl}pyrrolidin-3-ol
vernakalant	(3*R*)-1-{(1*R*,2*R*)-2-[2-(3,4-diméthoxyphényl)éthoxy]= cyclohexyl}pyrrolidin-3-ol
vernakalant	(3*R*)-1-{(1*R*,2*R*)-2-[2-(3,4-dimetoxifenil)etoxi]ciclohexil}pirrolidin-3-ol

$C_{20}H_{31}NO_4$



votucalisum*

votucalis	methionyl[145-leucine]FS-HBP2 (*Rhipicephalus appendiculatus* (Brown ear tick) Female-Specific Histamine-Bending Protein 2)
votucalis	méthionyl[145-leucine]FS-HBP2 (Protéine 2 se liant à l'histamine spécifique à la tique femelle *Rhipicephalus appendiculatus*)
votucalis	metionil[145-leucina]FS-HBP2 (Proteína 2 que se une a la histamina específica de la garrapata hembra *Rhipicephalus appendiculatus*)

$C_{858}H_{1259}N_{221}O_{289}S_{10}$

```
                                                                M
NQPDWADEAA  NGAHQDAWKS  LKADVENVYY  MVKATYKNDP  VWGNDFTCVG      50
VMANDVNEDE  KSIQAEFLFM  NNADTNMQFA  TEKVTAVKMY  GYNRENAFRY     100
ETEDGQVFTD  VIAYSDDNCD  VIYVPGTDGN  EEGYELWTTD  YDNILANCLN     150
KFNEYAVGRE  TRDVFTSACL  E                                      171
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

48-169 119-148

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 14
(WHO Chronicle, Vol. 28, No. 10, 1974)

p. 4 **dimemorfanum**
dimemorfan *insert the following graphic formula:*



Dénominations communes internationales recommandées (DCI Rec.): Liste 14
(Chronique OMS, Vol. 28, No. 10, 1974)

p. 4 **dimemorfanum**
dimémorfane *insérer la formule développée suivante:*



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 14
(Crónica de la OMS, Vol. 28, No. 10, 1974)

p. 4 **dimemorfanum**
dimemorfano *insértese la formúla désarollada siguiente:*



Recommended International Nonproprietary Names (Rec. INN): List 34
Dénominations communes internationales recommandées (DCI Rec.): Liste 34
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 34
(WHO Drug Information, Vol. 8, No. 3, 1994)

	suprimáse	*insértese*
p. 167	afovirseno	afovirsén

Recommended International Nonproprietary Names (Rec. INN): List 37
Dénominations communes internationales recommandées (DCI Rec.): Liste 37
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 37
(WHO Drug Information, Vol. 11, No. 1, 1997)

	suprimáse	*insértese*
p. 41	fomivirseno	fomivirsén

Recommended International Nonproprietary Names (Rec. INN): List 39
Dénominations communes internationales recommandées (DCI Rec.): Liste 39
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 39
(WHO Drug Information, Vol. 12, No. 1, 1998)

	suprimáse	*insértese*
p. 57	trecovirseno	trecovirsén

Recommended International Nonproprietary Names (Rec. INN): List 47
Dénominations communes internationales recommandées (DCI Rec.): Liste 47
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 47
(WHO Drug Information, Vol. 16, No. 1, 2002)

	suprimáse	*insértese*
p. 84	alicaforseno	alicaforsén

Recommended International Nonproprietary Names (Rec. INN): List 49
Dénominations communes internationales recommandées (DCI Rec.): Liste 49
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 49
(WHO Drug Information, Vol. 17, No. 2, 2003)

	suprimáse	*insértese*
p. 129	oblimerseno	oblimersén

Recommended International Nonproprietary Names (Rec. INN): List 51
Dénominations communes internationales recommandées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

	suprimáse	*insértese*
p. 85	aprinocarseno	aprinocarsén

Recommended International Nonproprietary Names (Rec. INN): List 57
Dénominations communes internationales recommandées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 55 **aclidinii bromidum**

bromuro de aclidinio

sustitúyase el nombre químico por el siguiente:

bromuro de (3*R*)-1-(3-fenoxipropil)-3-[(hidroxibis(tiofen-2-il)acetiloxi)]-1-2-butil-3-{4-[3-(dibutilamino)propil]benzoil}- 1λ^5-azabiciclo[2.2.2]octan-1-ilio

* Electronic structure available on Mednet: http://mednet.who.int/
* Structure électronique disponible sur Mednet: http://mednet.who.int/
* Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.